Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort
. The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence
of efficacy of PTG-300 for the treatment in β-thalassemia.
Phase:
Phase 2
Details
Lead Sponsor:
Protagonist Therapeutics Protagonist Therapeutics, Inc.